BACKGROUND. Because of the immunosuppression required, heart-transplant recipients frequently have complications caused by cytomegalovirus (CMV), including pneumonia, esophagitis, gastritis, and a syndrome of fever, hepatitis, and leukopenia. We undertook a controlled trial to evaluate the prophylactic administration of ganciclovir to prevent CMV-induced disease after heart transplantation. METHODS. This randomized, double-blind, placebo-controlled trial was conducted at four centers. Before randomization, the patients were stratified into two groups: those who were seropositive for CMV before transplantation and those who were seronegative but who received hearts from seropositive donors. Ganciclovir was given intravenously at a dose of 5 mg per kilogram of body weight every 12 hours from postoperative day 1 through day 14, then at a dose of 6 mg per kilogram each day for 5 days per week until day 28. RESULTS. Among the seropositive patients, CMV illness occurred during the first 120 days after heart transplantation in 26 of 56 patients given placebo (46 percent), as compared with 5 of 56 patients treated with ganciclovir (9 percent) (P less than 0.001). Among 37 seronegative patients, CMV illness was frequent in both groups (placebo, 29 percent; ganciclovir, 35 percent; P not significant). From day 15 through day 60, the patients who took ganciclovir had significantly fewer urine cultures positive for CMV, but by day 90 there was no difference. More of the ganciclovir-treated patients had serum creatinine concentrations greater than or equal to 221 mumol per liter (2.5 mg per deciliter) (18 percent vs. 4 percent in the placebo group), but those elevations were transient. CONCLUSIONS. The prophylactic administration of ganciclovir after heart transplantation is safe, and in CMV-seropositive patients it reduces the incidence of CMV-induced illness.
Source Information
Department of Medicine, Stanford University School of Medicine, Calif. 94305.
This article has been cited by other articles:
Dumortier, J., Streblow, D. N., Moses, A. V., Jacobs, J. M., Kreklywich, C. N., Camp, D., Smith, R. D., Orloff, S. L., Nelson, J. A.
(2008). Human Cytomegalovirus Secretome Contains Factors That Induce Angiogenesis and Wound Healing. J. Virol.
82: 6524-6535
[Abstract][Full Text]
Nwakanma, L. U., Shah, A. S., Conte, J. V., Baumgartner, W. A.
(2008). Heart Transplantation. Card Surg Adult
3: 1539-1578
[Full Text]
Bolovan-Fritts, C. A., Trout, R. N., Spector, S. A.
(2007). High T-cell response to human cytomegalovirus induces chemokine-mediated endothelial cell damage. Blood
110: 1857-1863
[Abstract][Full Text]
Potena, L., Holweg, C. T. J., Vana, M. L., Bashyam, L., Rajamani, J., McCormick, A. L., Cooke, J. P., Valantine, H. A., Mocarski, E. S.
(2007). Frequent Occult Infection with Cytomegalovirus in Cardiac Transplant Recipients despite Antiviral Prophylaxis. J. Clin. Microbiol.
45: 1804-1810
[Abstract][Full Text]
Adler, S. P., Marshall, B.
(2007). Cytomegalovirus Infections. Pediatr. Rev.
28: 92-100
[Full Text]
Hoffman, F. M., Nelson, B. J., Drangstveit, M. B., Flynn, B. M., Watercott, E. A., Zirbes, J. M.
(2006). Caring for Transplant Recipients in a Nontransplant Setting. Crit Care Nurse
26: 53-73
[Full Text]
Medlicott, S. A. C., Coderre, S., Horne, G., Panaccione, R.
(2006). Multimodal Immunosuppressant Therapy in Steroid-Refractory Common Variable Immunodeficiency Sprue: A Case Report Complicating Cytomegalovirus Infection. INT J SURG PATHOL
14: 101-106
[Abstract]
Kalil, A. C., Levitsky, J., Lyden, E., Stoner, J., Freifeld, A. G.
(2005). Meta-Analysis: The Efficacy of Strategies To Prevent Organ Disease by Cytomegalovirus in Solid Organ Transplant Recipients. ANN INTERN MED
143: 870-880
[Abstract][Full Text]
Lindenfeld, J., Miller, G. G., Shakar, S. F., Zolty, R., Lowes, B. D., Wolfel, E. E., Mestroni, L., Page, R. L. II, Kobashigawa, J.
(2004). Drug Therapy in the Heart Transplant Recipient: Part I: Cardiac Rejection and Immunosuppressive Drugs. Circulation
110: 3734-3740
[Full Text]
Bolovan-Fritts, C. A., Trout, R. N., Spector, S. A.
(2004). Human Cytomegalovirus-Specific CD4+-T-Cell Cytokine Response Induces Fractalkine in Endothelial Cells. J. Virol.
78: 13173-13181
[Abstract][Full Text]
Streblow, D. N., Kreklywich, C., Yin, Q., De La Melena, V. T., Corless, C. L., Smith, P. A., Brakebill, C., Cook, J. W., Vink, C., Bruggeman, C. A., Nelson, J. A., Orloff, S. L.
(2003). Cytomegalovirus-Mediated Upregulation of Chemokine Expression Correlates with the Acceleration of Chronic Rejection in Rat Heart Transplants. J. Virol.
77: 2182-2194
[Abstract][Full Text]
Caliendo, A. M., St. George, K., Allega, J., Bullotta, A. C., Gilbane, L., Rinaldo, C. R.
(2002). Distinguishing Cytomegalovirus (CMV) Infection and Disease with CMV Nucleic Acid Assays. J. Clin. Microbiol.
40: 1581-1586
[Abstract][Full Text]
Griffiths, P. D.
(2002). The treatment of cytomegalovirus infection. J Antimicrob Chemother
49: 243-253
[Abstract][Full Text]
BRENNAN, D. C.
(2001). Cytomegalovirus in Renal Transplantation. J. Am. Soc. Nephrol.
12: 848-855
[Full Text]
(2000). Management of herpes virus infections following transplantation. J Antimicrob Chemother
45: 729-748
[Full Text]
Sia, I. G., Patel, R.
(2000). New Strategies for Prevention and Therapy of Cytomegalovirus Infection and Disease in Solid-Organ Transplant Recipients. Clin. Microbiol. Rev.
13: 83-121
[Abstract][Full Text]
Valantine, H. A., Gao, S.-Z., Menon, S. G., Renlund, D. G., Hunt, S. A., Oyer, P., Stinson, E. B., Brown, B. W. Jr, Merigan, T. C., Schroeder, J. S.
(1999). Impact of Prophylactic Immediate Posttransplant Ganciclovir on Development of Transplant Atherosclerosis : A Post Hoc Analysis of a Randomized, Placebo-Controlled Study. Circulation
100: 61-66
[Abstract][Full Text]
Hunt, S. A.
(1998). Current Status of Cardiac Transplantation. JAMA
280: 1692-1698
[Abstract][Full Text]
Salzberger, B., Bowden, R. A., Hackman, R. C., Davis, C., Boeckh, M.
(1997). Neutropenia in Allogeneic Marrow Transplant Recipients Receiving Ganciclovir for Prevention of Cytomegalovirus Disease: Risk Factors and Outcome. Blood
90: 2502-2508
[Abstract][Full Text]
Kroshus, T. J., Kshettry, V. R., Savik, K., John, R., Hertz, M. I., Bolman, R. M. III
(1997). RISK FACTORS FOR THE DEVELOPMENT OF BRONCHIOLITIS OBLITERANS SYNDROME AFTER LUNG TRANSPLANTATION. J. Thorac. Cardiovasc. Surg.
114: 195-202
[Abstract][Full Text]
Lemstrom, K., Sihvola, R., Bruggeman, C., Hayry, P., Koskinen, P.
(1997). Cytomegalovirus Infection–Enhanced Cardiac Allograft Vasculopathy Is Abolished by DHPG Prophylaxis in the Rat. Circulation
95: 2614-2616
[Abstract][Full Text]
Crumpacker, C. S.
(1996). Ganciclovir. NEJM
335: 721-729
[Full Text]
Spector, S. A., McKinley, G. F., Lalezari, J. P., Samo, T., Andruczk, R., Follansbee, S., Sparti, P. D., Havlir, D. V., Simpson, G., Buhles, W., Wong, R., Stempien, M. J., The Roche Cooperative Oral Ganciclovir Study Group,
(1996). Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Persons with AIDS. NEJM
334: 1491-1497
[Abstract][Full Text]
Merigan, T. C.
(1995). A Quarter-Century of Antiviral Therapy. NEJM
333: 1704-1705
[Full Text]
Valantine, H. A., Schroeder, J. S.
(1995). Recent Advances in Cardiac Transplantation. NEJM
333: 660-662
[Full Text]
Wechsler, M. E., Giardina, E.-G. V., Sciacca, R. R., Rose, E. A., Barr, M. L.
(1995). Increased Early Mortality in Women Undergoing Cardiac Transplantation. Circulation
91: 1029-1035
[Abstract][Full Text]
Pizzo, P. A.
(1993). Management of Fever in Patients with Cancer and Treatment-Induced Neutropenia. NEJM
328: 1323-1332
[Full Text]
(1992). GANCICLOVIR PROTECTS AGAINST CMV INFECTION AFTER HEART TRANSPLANT. JWatch General
1992: 4-4
[Full Text]
Previous
